BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

Area of Science:

• Oncology
• Genetics

Background:

• Melanoma incidence has risen, with metastatic disease significantly reducing survival.
• BRAF gene mutations drive melanoma and are present in approximately 50% of cutaneous melanomas.

Purpose of the Study:

• To provide evidence-based recommendations for implementing BRAF mutation testing and targeted therapy in metastatic melanoma patients in the U.K.
• To guide the practical application of vemurafenib and its companion diagnostic test.

Main Methods:

• Convened an expert panel to review evidence and formulate recommendations.
• Recommendations were reviewed by melanoma specialists and patient advocacy groups.

Main Results:

• Vemurafenib is the first licensed BRAF inhibitor for metastatic melanoma with BRAF mutations.
• A companion diagnostic, the cobas 4800 BRAF V600 Mutation Test, was developed alongside vemurafenib.

Conclusions:

• Implementation of BRAF mutation testing and targeted therapy is crucial for managing metastatic melanoma.
• These recommendations serve as a starting point for personalized melanoma treatment, subject to future updates based on clinical experience.